MX2016005287A - Metodos para el tratamiento de distrofias musculares. - Google Patents
Metodos para el tratamiento de distrofias musculares.Info
- Publication number
- MX2016005287A MX2016005287A MX2016005287A MX2016005287A MX2016005287A MX 2016005287 A MX2016005287 A MX 2016005287A MX 2016005287 A MX2016005287 A MX 2016005287A MX 2016005287 A MX2016005287 A MX 2016005287A MX 2016005287 A MX2016005287 A MX 2016005287A
- Authority
- MX
- Mexico
- Prior art keywords
- treatment
- methods
- muscular dystrophies
- composition
- dystrophy
- Prior art date
Links
- 201000006938 muscular dystrophy Diseases 0.000 title 1
- 239000000203 mixture Substances 0.000 abstract 2
- 206010013801 Duchenne Muscular Dystrophy Diseases 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 239000002207 metabolite Substances 0.000 abstract 1
- 210000003205 muscle Anatomy 0.000 abstract 1
- 229940002612 prodrug Drugs 0.000 abstract 1
- 239000000651 prodrug Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4166—1,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physical Education & Sports Medicine (AREA)
- Epidemiology (AREA)
- Neurology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Nutrition Science (AREA)
- Rheumatology (AREA)
- Physiology (AREA)
- Cardiology (AREA)
- Diabetes (AREA)
- Pain & Pain Management (AREA)
- Heart & Thoracic Surgery (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
La presente invención se relaciona con, inter alia, el tratamiento de distrofia muscular (por ejemplo, Distrofia Muscular de Duchenne), por ejemplo, utilizando una composición, por ejemplo, una composición que comprende el Compuesto (I), o una sal farmacéuticainente aceptable, profármaco o metabolito del mismo.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361895832P | 2013-10-25 | 2013-10-25 | |
| PCT/US2014/062178 WO2015061685A1 (en) | 2013-10-25 | 2014-10-24 | Methods for treatment of muscular dystrophies |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2016005287A true MX2016005287A (es) | 2017-02-22 |
Family
ID=52993619
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2016005287A MX2016005287A (es) | 2013-10-25 | 2014-10-24 | Metodos para el tratamiento de distrofias musculares. |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US20160250188A1 (es) |
| EP (1) | EP3060206A4 (es) |
| JP (1) | JP2016538269A (es) |
| CN (1) | CN105979943A (es) |
| AU (1) | AU2014339917A1 (es) |
| BR (1) | BR112016009214A8 (es) |
| CA (1) | CA2928235A1 (es) |
| MX (1) | MX2016005287A (es) |
| WO (1) | WO2015061685A1 (es) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2643856B1 (es) | 2016-05-24 | 2018-08-03 | Universidad Del Pais Vasco / Euskal Herriko Unibertsitatea | Triazoles para la regulación de la homeostasis de calcio intracelular |
| AU2018225163A1 (en) * | 2017-02-22 | 2019-09-19 | Bioincept, Llc | Peptides and methods of treating dystrophy-related disorders using the same |
| EP3801510B1 (en) * | 2018-06-05 | 2025-04-23 | The Regents of the University of California | Compounds increasing the expression of sarcospan for use in the treatment of muscular dystrophy |
| US12441716B2 (en) | 2019-04-12 | 2025-10-14 | The Regents Of The University Of California | Compositions and methods for increasing muscle mass and oxidative metabolism |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0715087D0 (en) * | 2007-08-03 | 2007-09-12 | Summit Corp Plc | Drug combinations for the treatment of duchenne muscular dystrophy |
| GB2463514C (en) * | 2008-09-11 | 2018-09-26 | Galapagos Nv | Imidazolidine compounds and uses therefor |
| ITBO20090078A1 (it) * | 2009-02-13 | 2010-08-14 | Consiglio Nazionale Ricerche | Composti per il trattamento del tumore alla prostata e procedimenti per la loro sintesi |
-
2014
- 2014-10-24 CA CA2928235A patent/CA2928235A1/en not_active Abandoned
- 2014-10-24 US US15/031,139 patent/US20160250188A1/en not_active Abandoned
- 2014-10-24 WO PCT/US2014/062178 patent/WO2015061685A1/en not_active Ceased
- 2014-10-24 MX MX2016005287A patent/MX2016005287A/es unknown
- 2014-10-24 JP JP2016526156A patent/JP2016538269A/ja active Pending
- 2014-10-24 AU AU2014339917A patent/AU2014339917A1/en not_active Abandoned
- 2014-10-24 BR BR112016009214A patent/BR112016009214A8/pt not_active Application Discontinuation
- 2014-10-24 CN CN201480070003.0A patent/CN105979943A/zh active Pending
- 2014-10-24 EP EP14856707.6A patent/EP3060206A4/en not_active Ceased
-
2018
- 2018-10-24 US US16/169,019 patent/US20190167640A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| EP3060206A1 (en) | 2016-08-31 |
| AU2014339917A1 (en) | 2016-05-12 |
| BR112016009214A8 (pt) | 2020-03-24 |
| CA2928235A1 (en) | 2015-04-30 |
| WO2015061685A1 (en) | 2015-04-30 |
| JP2016538269A (ja) | 2016-12-08 |
| CN105979943A (zh) | 2016-09-28 |
| EP3060206A4 (en) | 2017-04-19 |
| US20160250188A1 (en) | 2016-09-01 |
| US20190167640A1 (en) | 2019-06-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12019501321A1 (en) | Methods of treating or preventing cholesterol related disorders | |
| PH12015502031B1 (en) | Tetrahydropyrrolothiazine compounds | |
| PH12016500169A1 (en) | Polymorph of syk inhibitors | |
| UA117976C2 (uk) | Сполуки амінопіримідинілу як інгібітори jak | |
| MX2015005858A (es) | Moduladores del receptor acoplado a proteina g (gpr40) de dihidropirazol. | |
| MX361499B (es) | Baricitinib deuterado. | |
| MX358499B (es) | Moduladores de dihidropirazol del receptor acoplado a la proteína g (gpr40). | |
| NZ708501A (en) | Treatment of pulmonary disease | |
| EA201591805A1 (ru) | Оксабицикло [2.2.2] кислоты - модуляторы gpr120 | |
| IN2015DN00598A (es) | ||
| NZ729037A (en) | Carboxylic acid compound, method for preparation thereof, and use thereof | |
| MX2015005720A (es) | Moduladores de dihidropirazol de receptor acoplado a la proteina g (gpr40). | |
| MY197698A (en) | Oxysterols and methods of use thereof | |
| MY187718A (en) | Pharmaceutical formulations | |
| EA201490756A1 (ru) | Разагилина цитрамид | |
| GEP20166444B (en) | Epoxyeicosatrienoic acid analogs and methods of making and using the same | |
| MX2015015562A (es) | Dihidropiridinona como inhibidores de monoacilglicerol aciltransferasa 2. | |
| MX2016010973A (es) | Compuestos de aminocarbonilcarbamato. | |
| MX362879B (es) | Usos novedosos. | |
| MY162886A (en) | Novel tetrahydropyridopyrimidine compound or salt thereof | |
| WO2014159794A3 (en) | Bicyclo [2.2.1] acid gpr120 modulators | |
| IN2014DN07996A (es) | ||
| PH12018500903A1 (en) | Pyranodipyridine compound | |
| MX2016005287A (es) | Metodos para el tratamiento de distrofias musculares. | |
| PH12017501404A1 (en) | Diaza-benzofluoranthrene compounds |